We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biological Markers in Tears May Diagnose PD

By LabMedica International staff writers
Posted on 15 Mar 2018
Print article
Image: The Schirmer’s test is an invasive filter paper strip folded over the lower lid to absorb the tear film for five minutes. The tears collected on the Schirmer’s strips can be analyzed for biomarkers (Photo courtesy of Innovative Eye Care).
Image: The Schirmer’s test is an invasive filter paper strip folded over the lower lid to absorb the tear film for five minutes. The tears collected on the Schirmer’s strips can be analyzed for biomarkers (Photo courtesy of Innovative Eye Care).
Parkinson's disease is a progressive disorder that kills brain cells that produce dopamine, which is a chemical messenger important for the control of movement. The main symptoms of Parkinson's include slowness of movement, tremors, rigidity, and difficulty maintaining balance and coordination.

Tear samples from individuals with Parkinson's disease (PD) had different levels of a protein linked to the disease than those who did not have it. Such a marker could be very useful in helping to diagnose, and perhaps even treat Parkinson's because the disease can begin many years before its symptoms appear.

Scientists at the University of Southern California (Los Angeles, CA, USA) and their colleagues compared tear samples from 55 PD patients of varying severity and 27 age- and gender-matched non-PD controls were collected and pooled from both eyes for analysis of alpha synuclein, CC chemokine ligand 2 (CCL-2) and DJ-1 (Parkinson’s disease protein 7) using a Human magnetic Luminex assay kit and analysis of oligomeric alpha-synuclein using an Human alpha-synuclein oligo enzyme-linked immunosorbent assay (ELISA) kit, respectively.

The team revealed that total alpha-synuclein decreased significantly in PD patients (423.12 ± 52.6 pg/mg tear protein) relative to healthy controls (703.61 ± 136.4 pg/mg tear protein) in tears from patients acquired from Schirmer’s strips taken during an anesthetized Schirmer’s test. Oligomeric alpha-synuclein increased significantly in PD patients (1.45 ± 0.31 ng/mg tear protein) relative to controls (0.27 ± 0.07 ng/mg tear protein). While detectable in tears, neither CCL-2 nor DJ-1 varied between PD patients and non-PD controls.

While it is not yet clear how Parkinson's disease kills brain cells, scientists have discovered that toxic protein deposits known as Lewy bodies are often present in many brain cells of people with the disease. These deposits contain clusters of proteins that have not folded correctly. A major component of Lewy bodies is an oligomeric form of the protein alpha-synuclein. The oligomeric form of a protein comprises several repeats of the protein's essential amino acids, but not as many as the polymeric form. An author of a recently published study of alpha-synuclein in Parkinson's has suggested that the oligomeric protein's ability to "disrupt the integrity of the membrane" might be a key step in the process that ultimately kills the cell.

Mark F. Lew, MD, a professor of Neurology and lead investigator in the study, said, “We believe our study is the first to show that tears may be a reliable, inexpensive, and noninvasive biological marker of Parkinson's disease.” The study will be presented at the 70th annual meeting of the American Academy of Neurology, which will be held April 21-27, 2018, in Los Angeles, CA, USA.

Related Links:
University of Southern California

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.